“It was July 9, 2021, at 9 a.m. NBC’s ‘Today’ show was on television in our house that morning. I was in my home office going through my morning routine while my wife, Susan, was downstairs in her home office. “When my cellphone rang, I recognized the number as the…
CS Pharmaceuticals (CSP) has entered into an exclusive in-licensing agreement with Daewoong Pharmaceutical to develop and commercialize bersiporocin, an oral experimental anti-fibrotic medication for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases in the greater China region. “This will be the stepping stone towards becoming a game…
Whenever my family visits my husband and me here in Hawaii, I can’t help but reflect on my first trip to the islands right before my mom, Holly, was hospitalized for an acute exacerbation of her idiopathic pulmonary fibrosis (IPF). That 2018 visit was our first real family vacation…
The U.S. Food and Drug Administration (FDA) has granted INS018_055 orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF), the therapy’s developer Insilico Medicine, announced. Insilico is expecting to initiate a global Phase 2 clinical trial testing INS018_055 in people with IPF later this year. Orphan drug…
Living with a chronic illness takes commitment, patience, and endurance. A lot of energy is required to manage your disease, medication schedules, procedures, and medical equipment. For me, equipment management means keeping my oxygen tanks in working order, as I’ve relied on them to breathe since I was diagnosed…
On Jan. 18, Larry Runyon passed away at 76. Larry was a warrior fighting idiopathic pulmonary fibrosis (IPF) for more than 15 years. He’s certainly not the first person I’ve known who has passed because of IPF, but he is the first one to pass whom I’ve known for…
Dosing has begun in a clinical trial evaluating ARO-MMP7, Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy for idiopathic pulmonary fibrosis (IPF). Expecting to enroll up to 56 healthy volunteers and 21 adults with IPF, the Phase 1/2a trial (NCT05537025) — dubbed AROMMP7-1001 — will evaluate the therapy’s…
Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders. In Boehringer…
There are certain moments in our lives when a single event becomes indelibly etched into our memory. And the significance of such moments is dictated by each of us. Think about that for a minute. What moments are etched into your memory? Have you dealt with the loss of a…
The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and safely — improve lung function in people with idiopathic pulmonary fibrosis (IPF), outperforming all lower doses in a Phase 2a trial. Three-month data from the INTEGRIS-IPF trial (NCT04396756)…
Get regular updates to your inbox.
